Methoxychalcone inhibitors of androgen receptor translocation and function.

Bioorg Med Chem Lett

Medical Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, United States.

Published: March 2012

Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308679PMC
http://dx.doi.org/10.1016/j.bmcl.2011.12.141DOI Listing

Publication Analysis

Top Keywords

androgen receptor
12
methoxychalcone inhibitors
4
androgen
4
inhibitors androgen
4
receptor
4
receptor translocation
4
translocation function
4
function androgen
4
receptor activity
4
activity drives
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!